Literaturnachweis - Detailanzeige
Autor/inn/en | Hardan, Antonio Y.; Jou, Roger J.; Handen, Benjamin L. |
---|---|
Titel | Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders |
Quelle | In: Journal of Autism and Developmental Disorders, 35 (2005) 3, S.387-391 (5 Seiten)
PDF als Volltext |
Sprache | englisch |
Dokumenttyp | gedruckt; online; Zeitschriftenaufsatz |
ISSN | 0162-3257 |
DOI | 10.1007/s10803-005-3306-1 |
Schlagwörter | Narcotics; Drug Therapy; Children; Adolescents; Pervasive Developmental Disorders; Medical Services; Developmental Disabilities; Outcomes of Treatment; Measures (Individuals) |
Abstract | A retrospective study was conducted in a clinic specialized in treating individuals with developmental disabilities to examine the effectiveness and tolerability of quetiapine in children and adolescents with pervasive developmental disorders. Ten consecutive outpatients (age = 12.0 [plus or minus] 5.1 years) treated with quetiapine (dose = 477 [plus or minus] 212 mg, duration = 22.0 [plus or minus] 10.1 weeks) were identified and six were judged to be responders based on impressions from chart review and Conners Parent Scale (CPS). Improvements were observed in the conduct, inattention, and hyperactivity subscales of the CPS. Adverse events were mild with sedation being the most common, and no patient required treatment termination. Quetiapine may be beneficial in children and adolescents with pervasive developmental disorders, however open-label and double-blind, placebo-controlled studies are warranted. (Author). |
Anmerkungen | Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: service-ny@springer.com; Web site: http://www.springerlink.com. |
Erfasst von | ERIC (Education Resources Information Center), Washington, DC |
Update | 2017/4/10 |